Research advancement in effects of gene single nucleotide polymorphism to platinum drugs' chemotherapy sensitivity in NSCLC patients

Abstract

Abstract: By Consulting the papers at home and abroad, we summarize the effect of gene single nucleotide polymorphism to platinum drugs in non-small cell lung cancer (NSCLC)patients. The result is there existing huge interindividual variability on the sensitivity of platinum drugs in NSCLC patients. The gene SNP is an important factor to the chemotherapy therapeutic effect of platinum drugs. Better therapeutical effect will show up when taking medicine individually in case of the gene types of NSCLC patients are definite.

Key words: NSCLC, Platinum drugs, Single nucleotide polymorphism

CLC Number:

R969

ZHAO Gang-tao, YANG Fan, DING Yuan-yuan, ZHENG Fei, ZENG Ming, ZHAO Wei-juan, XU Jing-feng. Research advancement in effects of gene single nucleotide polymorphism to platinum drugs' chemotherapy sensitivity in NSCLC patients[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2010, 15(6): 715-720.

References

[1] 于庆忠,韩金祥,潘继红,等. NSCLC患者XPG、MDR-1基因单核苷酸多态性与铂类药物化疗疗效的关系[J]. 山东医药,2007,47(9):7-9.
[2] Kim DH, Park JY, Sohn SK, et al. Multidmg resistance-1 gene polymorphisms associated with treatment outcomes in de novo acute myelo id leukem ia [J]. Int J Cancer, 2006, 118 (9): 2195-2201.
[3] 魏嘉,刘宝瑞,王亚平,等. DNA修复基因单核苷酸多态性与铂类药物抵抗研究进展[J]. 中华肿瘤杂志,2006,28(3):161-163.
[4] 江艺,邱希辉,林丹霞,等. 铂类联合多西他赛一线治疗晚期食管癌[J]. 中国临床药理学与治疗学,2009,14(12):1395-1399.
[5] Stoehlmacher J, Ghaderi V, Iobal S, et al. A polymorphism of the XRCC1 gene predicts for response to platinum based treatment in advanced colorectal cancer [J]. Anticancer Res, 2001, 21: 3075-3079.
[6] 袁芃,缪小平,张雪梅,等. DNA损伤修复基因XRCC1和XPD遗传多态与晚期非小细胞肺癌对铂类药物的敏感性[J]. 中华肿瘤杂志,2006,28(3):196-199.
[7] 邱立新,钱晓萍,刘宝瑞,等. XRCC1基因多态性与晚期非小细胞肺癌铂类药物化疗敏感性的关系[J]. 现代肿瘤医学,2009,17(2):263-265.
[8] 王中华,缪小平,谭文,等. XRCC1单核苷酸多态与晚期非小细胞肺癌对铂类药物敏感性的相关性[J]. 癌症,2004,23(8):865-868.
[9] 戴穹,杨志惠. DNA修复基因XRCC3 Thr241Met多态性在四川汉族人群的分布[J]. 泸州医学院学报,2007,30(1):11-14.
[10] Monzo M, Brunet S, Urbano-Isp izua A, et al. Genomic polymorphisms provide prognostic information in intermediaterisk acute myeloblastic leukemia [J]. Blood, 2006, 107 (12):4871-4879.
[11] 袁芃,缪小平,张雪梅,等. XPC和XPD基因遗传多态与晚期非小细胞肺癌对铂类药的敏感性[J]. 中华医学杂志,2005,85(14):972-975.
[12] 陈健,何义富,胡冰. 核苷酸切除修复基因多态性和铂类药物耐药性关系研究进展[J]. 现代肿瘤医学,2009,17(4):763-766.
[13] Gurubhagavatula S, Liu G, Park S, et al. XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy [J]. J Clin Oncol, 2004, 22 (13):2594-2601.
[14] 丁忠海. DNA修复基因XPD751基因多态性与肺癌化疗敏感性的关系研究[D].南京医科大学学位论文,2008.6
[15] Jeon HS, Kim KM, Park SH, et al. Relationship between XPG codon 1104 polymorphism and risk of primary lung cancer[J]. Carcinogenesis, 2003, 24: 1677-1681.
[16] Vila JM, Moreno I, MonzoM, et al. XPD, XPA, ERCC1 and XPG/ERCC5 single nucleotide polymorphisms ( SNPs) in oxaliplatin-treated colorectal cancer (CRC) [J]. Clin Oncol, 2004, 22: 3677.
[17] Bellmunt J, Paz Ares L, Cuello M, et al . Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy [J].Ann Oncol, 2007, 18 (3) :522-528.
[18] 周伟华,邓觐云. ERCC1及其基因多态性与铂类耐药的相关性[J]. 江西医药,2009,44(2):179-182.
[19] Steffensen KD, Waldstrom M, Jeppesen U,et al. Prediction of response to chemotherapy by ERCC1 immunohistochemistry and ERCC1 poly-morphism in ovarian cancer[J]. Int J Gynecol Cancer,2008,18(4):702.
[20] 袁芃,缪小平,张雪梅,等. 晚期非小细胞肺癌对铂类药物的化疗敏感性与p53和p73基因多态的关系[J]. 中华肿瘤杂志,2006,28(2):107-110.
[21] 茆勇,黄朝晖,华东,等. 谷胱甘肽S转移酶基因多态性与NSCLC化疗疗效的关系[J]. 山东医药,2007,47(36):68-69.